Results 261 to 270 of about 810,282 (282)

Engineering recombinant antibodies for immunotherapy

Cell Biophysics, 1995
Recombinant antibody fragments binding with high affinity to their target can be obtained either from hybridomas or directly from antibody libraries on filamentous phage. These fragments are devoid of any activity other than antigen binding, and have to be processed and functionalized in order to be suitable for clinical applications.
D, Neri, H, Petrul, G, Roncucci
openaire   +2 more sources

Advances in recombinant antibody microarrays

Clinica Chimica Acta, 2004
Antibody microarrays, one emerging class of proteomic technologies, have broad applications in proteome analysis, disease diagnostics and quantitative analysis. Compared to DNA microarrays, protein targets have significantly more complex interactions with their ligands such as antibodies.
Petra, Pavlickova, E Marion, Schneider, Hubert, Hug   +2 more
openaire   +2 more sources

Selection of Recombinant Human Antibodies

2015
Since the development of therapeutic antibodies the demand of recombinant human antibodies is steadily increasing. Traditionally, therapeutic antibodies were generated by immunization of rat or mice, the generation of hybridoma clones, cloning of the antibody genes and subsequent humanization and engineering of the lead candidates.
Florian, Tomszak, Susanne, Weber, Jonas, Zantow, Thomas, Schirrmann, Michael, Hust, André, Frenzel   +5 more
openaire   +2 more sources

Glycosylation of Recombinant Antibody Therapeutics

Biotechnology Progress, 2008
The adaptive immune system has the capacity to produce antibodies with a virtually infinite repertoire of specificities. Recombinant antibodies specific for human targets are established in the clinic as therapeutics and represent a major new class of drug.
openaire   +2 more sources

Recombinant antibodies for cancer therapy

Expert Opinion on Biological Therapy, 2008
Recombinant antibodies have evolved into successful therapeutics with 10 approved for cancer and more in the pipeline. Four of the top ten cancer therapy drugs are recombinant antibodies.To survey the current state-of-the-art highlighting the reasons for this success and looking ahead to the next generation of antibody therapy.An analysis was carried ...
openaire   +2 more sources

[Antithrombotic recombinant antibodies].

Journal de la Societe de biologie, 2007
Coronary syndromes, stroke and other ischaemic arterial diseases are the leading cause of death in the world and will probably remain it at least until 2020. Cardiovascular diseases kill 17 million people each year with an expected increase to 20 million in 2020 and 24 million in 2030.
Julien, Muzard, Stéphane, Loyau, Nadine, Ajzenberg, Philippe, Billiald, Martine, Jandrot-Perrus   +4 more
openaire   +1 more source

Selection of Recombinant Antibodies from Antibody Gene Libraries

2013
Antibodies are indispensable detection reagents for research and diagnostics and represent the biggest class of biological therapeutics on the market. In vitro antibody selection systems offer many advantages over animal-based technologies because the whole selection process is independent of the in vivo immune response.
Michael, Hust, André, Frenzel, Thomas, Schirrmann, Stefan, Dübel   +3 more
openaire   +2 more sources

Selection of Recombinant Antibodies From Antibody Gene Libraries

2007
After the sequencing of the human genome is completed, the research focus shifts toward the analysis of gene products. The human genome encodes more than 30,000 genes. Owing to alternative mRNA splicing and posttranslational modifications, for example, glycosylation, phoshorylation, and so on, the number of different proteins of human proteome is ...
Michael, Hust, Stefan, Dübel, Thomas, Schirrmann   +2 more
openaire   +2 more sources

Recombinant Antibodies for the Generation of Antibody Arrays

2011
Affinity proteomics, mainly represented by antibody microarrays, has in recent years been established as a powerful tool for high-throughput (disease) proteomics. The technology can be used to generate detailed protein expression profiles, or protein maps, of focused set of proteins in crude proteomes and potentially even high-resolution portraits of ...
Carl A K, Borrebaeck, Christer, Wingren
openaire   +2 more sources

Recombinant Proteins and Monoclonal Antibodies

2017
The human genome has become a subject of public interest, whilst the proteome remains the province of specialists. Less appreciated is the human glycoprotein (GP) repertoire (proteoglycome!); however, some 50% of open reading frame genes encode for proteins (P) that may accept the addition of N-linked and/or O-linked sugar chains (oligosaccharides). It
openaire   +2 more sources